rocagl
class
natur
compound
isol
plant
genu
aglaia
potent
inhibitor
translat
initi
propos
form
stack
interact
polypurin
sequenc
region
utr
select
mrna
therebi
clamp
rna
substrat
onto
caus
inhibit
translat
initi
complex
sinc
viru
replic
reli
host
translat
machineri
surpris
rocagl
silvestrol
broadspectrum
antivir
activ
unfortun
synthesi
silvestrol
sophist
timeconsum
thu
hamper
prospect
antivir
drug
develop
present
less
complex
structur
synthet
rocagl
novel
compound
potent
broadspectrum
antivir
activ
primari
cell
ex
vivo
bronchial
epitheli
cell
system
inhibit
replic
corona
zika
lassa
crimean
congo
hemorrhag
fever
virus
lesser
extent
hepat
e
viru
hev
noncytotox
low
nanomolar
concentr
sinc
hev
polypurinefre
fold
stabl
hairpin
structur
hypothes
rna
clamp
silvestrol
deriv
may
also
occur
polypurineindepend
structuredepend
manner
interestingli
hev
confer
sensit
toward
silvestrol
howev
expos
polypurin
stretch
introduc
hev
becam
activ
inhibitor
compar
silvestrol
moreov
thermodynam
destabil
hev
led
reduc
translat
inhibit
silvestrol
suggest
differ
rocagl
mode
action
probabl
engag
silvestrol
addit
dioxan
moieti
deadbox
rna
helicas
part
heterotrimer
translat
initi
complex
unwind
rna
secondari
structur
select
mrna
enabl
bind
preiniti
complex
pic
bhat
et
al
wolf
et
al
cell
critic
role
translat
protooncogen
mrna
complexstructur
wolf
et
al
rubio
et
al
viral
mrna
also
contain
structur
madhugiri
et
al
schlereth
et
al
suggest
viral
protein
synthesi
may
also
inde
shown
specif
inhibitor
silvestrol
plantderiv
rocagl
broadspectrum
antivir
activ
noncytotox
concentr
low
nanomolar
rang
et
al
silvestrol
inhibit
replic
rna
virus
repres
differ
viru
famili
ebola
ebov
corona
cov
zika
zikv
chikungunya
chikv
hepat
e
hev
virus
et
al
biedenkopf
et
al
elgner
et
al
glitscher
et
al
henss
et
al
notabl
silvestrol
show
good
bioavail
sarahdi
et
al
vivo
antivir
activ
todt
et
al
remark
low
http
receiv
septemb
receiv
revis
form
januari
accept
januari
cytotox
primari
cell
thu
open
broad
therapeut
window
futur
applic
date
howev
chemic
synthesi
silvestrol
remain
difficult
altern
strategi
highli
desir
exampl
structur
less
complex
natur
rocagl
antivir
activ
roca
et
al
lack
dioxan
moieti
silvestrol
pan
et
al
investig
antivir
activ
synthet
roca
analog
wolf
et
al
fig
compar
activ
silvestrol
show
similar
antivir
activ
merscov
zikv
lasv
cchfv
lesser
extent
hev
thu
identifi
anoth
rocagl
potent
broadspectrum
antivir
activ
howev
also
found
differenti
activ
two
compound
depend
viral
use
translat
inhibit
assay
shown
roca
clamp
rna
substrat
onto
requir
polypurin
sequenc
iwasaki
et
al
wherea
silvestrol
also
clamp
polypurinefre
viral
rna
substrat
provid
stabl
hairpin
structur
present
recent
publish
crystal
structur
human
complex
polypurin
rna
substrat
roca
iwasaki
et
al
explain
observ
polypurin
depend
roca
purin
effici
stack
phenyl
ring
roca
although
structurebas
inform
miss
suggest
dioxan
moieti
silvestrol
mediat
polypurinefre
rna
clamp
onto
human
fetal
lung
fibroblast
human
lung
carcinoma
cell
murin
hepatocyt
cell
grown
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
uml
penicillin
streptomycin
atmospher
contain
co
silvestrol
obtain
sarawak
biodivers
centr
kuch
northborneo
malaysia
puriti
mm
stock
solut
prepar
dmso
sterilefilt
roth
dilut
dmem
control
cell
treat
correspond
dmso
dilut
lack
silvestrol
wolf
et
al
dissolv
dmso
concentr
mm
store
cell
growth
viabil
murin
hepatocyt
cell
presenc
respect
compound
determin
atplit
assay
perkinelm
mtt
method
describ
previous
et
al
et
al
cell
viabil
cell
persist
infect
hev
determin
use
prestoblu
cell
viabil
reagent
thermo
fisher
scientif
treatment
substanc
respect
concentr
h
cryopreserv
normal
human
bronchial
epitheli
nhbe
cell
obtain
lonza
undifferenti
cell
seed
transwel
plate
corn
costar
coat
collagen
iv
invitrogen
grown
mixtur
dmem
invitrogen
begm
lonza
supplement
retino
acid
nm
fresh
medium
ad
regularli
day
reach
confluenc
cell
cultiv
airliquid
condit
addit
week
full
differenti
pseudostratifi
human
airway
epithelia
medium
basolater
compart
renew
everi
day
apic
surfac
wash
everi
week
pb
invitrogen
hightit
stock
ncbi
access
number
nc
merscov
produc
use
cell
hightit
stock
cchfv
strain
et
al
lasv
strain
lecompt
et
al
produc
vero
cell
zikv
strain
uganda
u
kindli
provid
european
viru
archiv
persist
hevinfect
cell
strain
genbank
id
previous
gener
john
et
al
determin
antivir
activ
silvestrol
cell
murin
hepatocyt
inocul
respect
viru
multipl
infect
moi
merscov
lasv
cchfv
h
inoculum
remov
cell
incub
fresh
medium
contain
inhibitor
increas
concentr
supernat
collect
h
post
infect
hpi
merscov
dpi
lasv
cchf
viru
titer
analyz
viru
plaqu
assay
et
al
immunofocu
assay
describ
et
al
calcul
ec
valu
viru
titer
determin
virusinfect
cell
treat
dmso
set
titer
obtain
treat
cell
normal
valu
ec
valu
calcul
nonlinear
regress
analysi
use
graphpad
prism
graphpad
softwar
infect
primari
human
airway
epitheli
cell
apic
surfac
wash
time
pb
cell
infect
moi
h
inoculum
remov
medium
basal
compart
replac
medium
contain
indic
inhibitor
concentr
indic
time
point
apic
surfac
cell
incub
pb
min
viru
titer
supernat
determin
viru
plaqu
assay
effect
hev
analyz
use
persist
hevinfect
cell
treatment
compound
start
h
post
seed
cell
cultur
supernat
analyz
h
via
qrtpcr
analyz
viral
protein
accumul
cell
infect
moi
inocul
supernat
replac
dmem
supplement
antibiot
indic
concentr
enantiom
hpi
cell
lysat
prepar
viral
protein
analyz
western
blot
describ
previous
et
al
cell
infect
moi
incub
h
indic
inhibitor
concentr
total
cellular
rna
isol
use
rneasi
kit
qiagen
qrtpcr
perform
use
ng
rna
luna
univers
probe
onestep
rtqpcr
kit
neb
sequenc
primer
use
amplifi
genom
total
viral
rna
respect
gapdh
mrna
avail
upon
request
analysi
rel
fold
viral
rna
express
regard
inhibitor
treatment
deltadelta
ct
method
use
gapdh
refer
use
livak
schmittgen
et
al
isol
quantif
extracellular
hev
rna
perform
describ
glitscher
et
al
construct
base
commerci
avail
plasmid
pfrhcvxb
addgen
produc
use
pcrbase
sitedirect
mutagenesi
primer
design
use
snapgen
gsl
biotech
llc
primer
sequenc
avail
upon
request
respect
clone
downstream
hsvtk
promotor
directli
follow
firefli
luciferas
gene
hcv
ire
renilla
luciferas
gene
total
length
analyz
includ
singlestrand
doublestrand
region
rang
bp
bp
ag
ac
dual
luciferas
report
assay
done
describ
previous
et
al
experi
perform
least
three
independ
replic
recent
shown
silvestrol
effici
inhibit
viral
protein
synthesi
merscovand
cell
et
al
investig
antivir
potenti
synthet
rocagl
lack
dioxan
moieti
silvestrol
fig
cell
infect
moi
effect
enantiom
viral
protein
synthesi
analyz
hpi
coronaviru
nucleoprotein
n
level
found
strongli
reduc
presenc
enantiom
concentr
nm
detect
effect
fig
similarli
genom
subgenom
rna
level
reduc
presenc
subnanomolar
concentr
fig
line
format
viral
replicationtranscript
complex
reduc
presenc
shown
immunofluoresc
analysi
use
antibodi
direct
nonstructur
protein
doublestrand
rna
dsrna
fig
next
analyz
effect
product
coronaviru
progeni
use
merscovinfect
cell
virus
reveal
reduc
viral
titer
effici
ec
valu
nm
nm
merscov
fig
concentr
nm
merscov
titer
reduc
log
level
suppl
fig
cytotox
test
use
cell
reveal
caus
slight
reduct
cell
viabil
respect
cell
incub
h
concentr
respect
compound
suppl
fig
indic
low
cytotox
compound
select
indic
see
tabl
even
cell
treat
extend
period
time
h
use
concentr
major
cytotox
effect
observ
fig
determin
cc
valu
racem
mixtur
use
rang
human
liver
skin
carcinoma
cell
line
well
primari
human
dermal
fibroblast
hdf
expect
cc
valu
analyz
cancer
cell
line
liver
skin
carcinoma
cell
line
found
low
nanomolar
rang
wherea
cc
primari
hdf
calcul
nm
fig
taken
togeth
data
demonstr
low
cytotox
primari
cell
compar
known
cytotox
effect
fast
grow
cancer
cell
line
evalu
antivir
potenti
silvestrol
relev
ex
vivo
system
respiratori
virus
use
primari
human
airway
epitheli
cell
cultur
normal
human
bronchial
epitheli
nhbe
cell
differenti
airliquid
condit
pseudostratifi
columnar
epithelia
epithelium
infect
mimic
viral
infect
differ
cell
type
human
airway
presenc
inhibitor
solvent
control
fig
concentr
nm
reduc
viru
titer
supernat
order
magnitud
use
cell
two
differ
donor
similar
antivir
effect
observ
nm
silvestrol
ex
vivo
model
nm
compound
reduc
infecti
viru
product
undetect
level
fig
c
wherea
nm
significantli
reduc
viral
replic
recent
shown
silvestrol
inhibit
zikv
replic
human
lung
epitheli
cell
line
primari
human
hepatocyt
elgner
et
al
present
studi
found
also
caus
strong
reduct
zikv
rna
level
calcul
ec
valu
nm
tabl
suppl
fig
assess
potenti
broadspectrum
antivir
activ
silvestrol
highli
pathogen
emerg
virus
analyz
effect
primari
murin
hepatocyt
infect
lasv
cchfv
fig
data
reveal
silvestrol
potent
antivir
activ
ec
valu
nm
detect
cytotox
concentr
fig
viru
titer
show
drop
lasvand
drop
cchfvinfect
cell
fig
c
furthermor
analyz
inhibit
hev
replic
fig
persist
hevinfect
cell
treat
differ
concentr
silvestrol
two
enantiom
hpi
extracellular
viral
rna
level
correl
releas
viral
particl
analyz
use
quantit
rtpcr
line
previou
result
glitscher
et
al
confirm
antivir
activ
silvestrol
antivir
effect
hev
found
slightli
weaker
low
nanomolar
concentr
use
assay
fig
howev
cytotox
silvestrol
alreadi
observ
concentr
nm
wherea
cytotox
concentr
yet
nm
cytotox
could
observ
reduc
viabil
persist
hevinfect
cell
fig
gain
mechanist
insight
effect
silvestrol
translat
initi
rna
clamp
compar
inhibitori
effect
two
rocagl
differ
viral
dual
luciferas
report
assay
fig
et
al
merscov
ebov
mrna
found
similarli
sensit
translat
inhibit
silvestrol
fig
contrast
ebov
insensit
sensit
silvestrol
interestingli
mrna
carri
like
inaccess
pentapurin
stretch
stem
structur
fig
howev
pentapurin
stretch
follow
decapurin
stretch
seem
unstructur
thu
predict
enabl
rna
clamp
iwasaki
et
al
second
purin
stretch
absent
hairpin
alon
suffici
mediat
translat
inhibit
silvestrol
surprisingli
hairpin
increas
report
activ
twofold
presenc
fig
increas
reduc
back
baselin
level
addit
ag
polypurin
stretch
insert
hairpin
also
insert
result
slightli
increas
translat
inhibit
silvestrol
indic
polypurin
sequenc
strengthen
inhibitori
effect
rocagl
fig
ag
confirm
idea
polypurin
requir
stabl
stack
interact
rocagl
construct
consist
long
ag
unstructur
ac
sequenc
neg
control
presum
silvestrol
inhibit
translat
ag
construct
even
concentr
nm
fig
remark
presenc
ac
sequenc
caus
induct
luciferas
activ
compound
fig
indic
helicas
activ
dispens
case
interestingli
hev
lack
polypurin
sequenc
element
predict
form
stabl
rna
hairpin
structur
like
requir
unwind
translat
initi
shown
hev
replic
inhibit
silvestrol
glitscher
et
al
slightli
lesser
extent
fig
therefor
ask
polypurinefre
hev
also
sensit
silvestrol
treatment
concentr
nm
silvestrol
hev
mediat
reduc
luciferas
activ
demonstr
silvestrol
inde
clamp
viral
rna
onto
importantli
case
treatment
fig
moreov
indic
dioxan
moieti
silvestrol
may
play
critic
role
clamp
structur
rna
onto
polypurineindepend
manner
test
assumpt
hev
hairpin
structur
thermodynam
destabil
disrupt
one
two
base
pair
stem
fig
chang
led
gradual
loss
inhibitori
effect
silvestrol
analyz
relev
polypurin
stretch
viral
sequenc
hev
chang
fig
therebi
introduc
stretch
consecut
purin
although
thermodynam
stabil
hairpin
structur
reduc
sequenc
chang
becam
sensit
silvestrol
treatment
fig
model
silvestrol
onto
surfac
structur
human
rna
complex
report
assay
result
indic
differ
mode
action
silvestrol
rocagl
lack
dioxan
moieti
sinc
structur
data
cocrystal
silvestrol
rna
avail
model
structur
silvestrol
publish
structur
surfac
iwasaki
et
al
compar
local
roca
silvestrol
found
dioxan
moieti
silvestrol
complet
cross
surfac
bound
rna
substrat
thu
enabl
silvestrol
make
addit
contact
eg
via
hbond
arginin
form
absenc
dioxan
moieti
fig
suggest
silvestrol
abl
clamp
rna
without
absolut
requir
stack
interact
purin
base
stabil
interact
proxim
side
bound
rna
may
suffici
lock
rna
helicas
identifi
synthet
rocagl
novel
potent
antivir
compound
broadspectrum
activ
merscov
lasv
cchfv
hev
zikv
moreov
antivir
potenti
silvestrol
compar
ex
vivo
human
airway
epitheli
cell
system
airliquid
condit
differenti
airway
epitheli
cell
use
model
primari
airway
defens
barrier
inhal
pathogen
mimick
natur
situat
infect
host
system
provid
pseudostratifi
organ
basal
ciliat
goblet
less
common
type
cell
play
crucial
role
maintain
airway
homeostasi
regul
innat
acquir
immun
product
wide
rang
cytokin
well
chemokin
davi
relev
ex
vivo
system
could
confirm
antivir
effect
well
silvestrol
replic
potent
antivir
activ
similar
complexstructur
silvestrol
activ
low
nanomolar
concentr
low
cytotox
primari
human
cell
higher
cytotox
cancer
cell
line
see
fig
thu
open
broad
therapeut
window
treatment
viral
infect
qualifi
interest
synthet
rocagl
vivo
evalu
even
though
antivir
potenti
similar
silvestrol
identifi
substanti
mechanist
differ
two
compound
detail
rna
gener
bind
sequenceand
structureindepend
manner
via
phosphat
backbon
thu
rna
clamp
rocagl
occur
activ
retain
abil
unwind
secondari
structur
bound
substrat
rna
report
assay
silvestrol
abl
clamp
polypurinefre
stabl
hairpin
structur
onto
wherea
requir
access
polypurinesequ
close
proxim
hairpin
conclus
support
data
show
translat
report
construct
contain
ebov
insensit
sensit
silvestrol
reduc
hairpin
stabil
correl
loss
silvestrol
sensit
suggest
thermodynam
stabil
hairpin
structur
critic
import
also
support
observ
introduct
unstructur
ac
sequenc
render
report
construct
insensit
silvestrol
wherea
ag
polypurin
sequenc
might
abl
form
stabl
hairpin
structur
make
nonwatsoncrick
ga
basepair
contact
strongli
requir
helicas
activ
remodel
structur
silvestrol
onto
surfac
publish
structur
reveal
silvestrol
principl
capabl
contact
via
phenylalanin
later
iwasaki
et
al
via
arginin
proxim
site
bound
substrat
rna
fig
lead
us
suggest
silvestrol
may
abl
clamp
rna
sequenc
onto
result
fig
indic
unstructur
sequenc
suffici
length
eg
ac
sequenc
requir
helicas
activ
allow
pic
bind
prerequisit
translat
initi
wherea
stabl
hairpin
structur
like
prevent
pic
bind
thu
need
unwound
publish
crystal
structur
human
complex
polypurin
rna
substrat
roca
iwasaki
et
al
help
explain
polypurin
sequenc
requir
clamp
rna
onto
roca
stack
interact
two
phenyl
ring
roca
two
consecut
purin
substrat
rna
stabl
enough
rna
clamp
onto
wherea
less
stabl
interact
pyrimidin
insuffici
iwasaki
et
al
consequ
stabl
hairpin
structur
without
polypurin
stretch
may
bound
effici
roca
due
lack
dioxan
moieti
date
structur
inform
exact
bind
mode
silvestrol
onto
therefor
initi
cocrystal
studi
human
polyag
rna
silvestrol
identifi
exact
posit
dioxan
moieti
surprisingli
observ
antivir
activ
hevproduc
cell
noncytotox
concentr
nm
even
though
compound
inhibit
report
translat
presenc
polypurinefre
propos
indirect
antivir
effect
could
caus
inhibit
cellular
mrna
unknown
ident
importantli
effect
vivo
compar
silvestrol
xenograft
mous
model
compound
reduc
tumor
growth
effici
wolf
et
al
treatment
chang
bodi
weight
number
blood
cell
toxic
could
observ
gastrointestin
tract
mice
moreov
serum
level
aminotransferas
alt
ast
albumin
total
bilirubin
well
creatinin
significantli
chang
two
week
cessat
treatment
indic
favor
toxic
profil
vivo
wolf
et
al
far
publish
data
pharmacokinet
properti
avail
alreadi
shown
daili
intraperiton
inject
work
well
mice
wolf
et
al
chan
et
al
system
avail
rocagl
follow
oral
applic
seem
limit
saradhi
et
al
base
data
conclud
may
repres
interest
altern
broadspectrum
antivir
silvestrol
remain
confirm
appropri
vivo
studi
evalu
compar
antivir
potenti
toxic
pharmacokinet
profil
two
compound
conclus
result
confirm
potent
broadspectrum
antivir
activ
similar
silvestrol
tabl
moreov
polypurin
sequenc
found
requir
rocaglatedepend
clamp
onto
dioxan
moieti
silvestrol
miss
shown
synthet
compound
data
also
suggest
silvestrol
retain
abil
clamp
rna
substrat
contain
stabl
hairpin
structur
case
polypurin
sequenc
access
see
caption
next
page
c
et
al
antivir
research
absent
see
hev
dioxan
moieti
silvestrol
abl
cross
rna
stretch
make
addit
contact
proxim
posit
arginin
residu
pymol
use
graphic
illustr
grey
rna
green
roca
purpl
silvestrol
cyan
